Delving into the Latest Updates on Semaglutide (Novo Nordisk) with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

Semaglutide, Semaglutide (Genetical Recombination), Semaglutide (genetical recombination) (JAN)

+ [24]

Target

GLP-1R

Action

agonists

Mechanism

GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)

Therapeutic Areas

Endocrinology and Metabolic DiseaseNervous System DiseasesCardiovascular Diseases+ [7]

Active Indication

Chronic Kidney DiseasesStrokeMyocardial Infarction+ [27]

Inactive Indication

AtherosclerosisChronic gastritisFibrosis, Liver+ [6]

Originator Organization

Novo Nordisk A/S

Active Organization

Novo Nordisk A/S

Novo Nordisk China Pharmaceuticals Co. Ltd.Zomagen Biosciences Ltd.

+ [7]

Inactive Organization-

License Organization

Novo Nordisk A/S

Merck & Co., Inc.

Sumitomo Pharma Co., Ltd.

Drug Highest PhaseApproved

First Approval Date

United States (05 Dec 2017),

Diabetes Mellitus, Type 2

RegulationBreakthrough Therapy (China), Priority Review (United States)

Login to view timeline

Structure/Sequence

Sequence Code 50953

Source: *****

Glucagon-like peptide 1 receptor agonists (GLP-1RA), such as Ozempic and Wegovy, have been rapidly adopted for the treatment of obesity in both youth and adults. However, despite this rapid adoption and the known GLP-1RA mechanism of action for weight loss, which targets brain circuits responsible for appetite and eating behaviors, almost nothing is known about how these drugs affect the brain in youth who are treated for obesity, or how these drugs affect the brain of youth differently from adults. The goal of the current study is to compare youth and adults with obesity who are treated a GLP-1RA and measure potential difference in GLP-1RA associated change in brain function, appetite, and eating behaviors.

Start Date01 May 2026

Sponsor / Collaborator

University of Colorado Denver

[+1]

NCT07090343

/ Not yet recruitingPhase 3IIT

Semaglutide for Reducing Cardiovascular Events in Patients Undergoing Transcatether Aortic Valve Replacement

This is a Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial evaluating the safety and efficacy of once-weekly semaglutide 2.4 mg in adult patients undergoing transcatheter aortic valve replacement (TAVR) for severe aortic stenosis (AS) who meet current clinical criteria for semaglutide treatment. A total of 826 participants will be randomized 1:1 to receive semaglutide or placebo as an add-on to standard-of-care, starting 3 months before TAVR and continuing for 24 months post-procedure. The primary endpoint is time to first occurrence of a composite of cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal stroke or transient ischemic accident (TIA), and hospitalization for heart failure (HF). The study is event-driven and powered to detect a 20% relative risk reduction in primary outcome events. This trial aims to address the unmet need for medical therapies that improve outcomes in patients with severe AS following TAVR, with potential for direct clinical implementation.

Start Date01 Apr 2026

Sponsor / Collaborator

Leids Universitair Medisch Centrum

NCT06913023

/ Not yet recruitingPhase 2/3IIT

Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus

The study aims to determine the short-term efficacy, mechanisms and safety of 24 weeks of placebo and semaglutide therapy in 74 KTR at risk of post-transplant diabetes mellitus (PTDM).

Start Date05 Jan 2026

Sponsor / Collaborator

University Health Network

100 Clinical Results associated with Semaglutide (Novo Nordisk)

Login to view more data

100 Translational Medicine associated with Semaglutide (Novo Nordisk)

Login to view more data

100 Patents (Medical) associated with Semaglutide (Novo Nordisk)

Login to view more data

304

Literatures (Medical) associated with Semaglutide (Novo Nordisk)

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Impact of semaglutide 2.4 mg on healthcare resource utilization and medical costs in patients with atherosclerotic cardiovascular disease in the United States (SHINE-ASCVD)

Article

Author: Zhao, Zhenxiang ; Alvarez, Sara ; Michalak, Wojciech ; Faurby, Mads ; Fitch, Angela

BACKGROUND:

Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality. Semaglutide 2.4 mg (Wegovy) has demonstrated improved outcomes in patients with overweight or obesity (ov/ob) and ASCVD, but its impact on medical costs and healthcare resource utilization (HCRU) remains unknown.

AIMS:

To compare all-cause medical costs and HCRU among patients with ov/ob and ASCVD treated with semaglutide 2.4 mg versus semaglutide-untreated controls.

MATERIALS AND METHODS:

This observational cohort study utilized Komodo's Healthcare Map and included patients with ov/ob and ≥1 diagnosis of ASCVD during the baseline period with ≥12 months of insurance coverage before and after the index date. Patients in the semaglutide 2.4 mg cohort initiated treatment after 4 June 2021 and stayed adherent. Semaglutide-untreated controls were randomly selected and 1:4 propensity score matched based on baseline demographics, clinical characteristics, medical costs, and HCRU. Medical costs and HCRU were compared using generalized linear models.

RESULTS:

770 semaglutide 2.4 mg-treated patients and 3,080 controls were included. In the year following treatment initiation, semaglutide 2.4 mg was associated with 22% lower mean medical costs versus controls (-$4,639 per patient per year [PPPY]; cost ratio = 0.78, 95% confidence interval [CI] 0.67, 0.89). This difference is mainly due to lower inpatient costs with semaglutide 2.4 mg, which were 65% lower than controls (-$3,593; cost ratio = 0.35 [95% CI 0.21, 0.49]), along with a 48% lower inpatient visit rate (0.08 vs. 0.15; rate ratio = 0.52 [95% CI 0.34, 0.70]).

LIMITATIONS:

Limitations inherent to retrospective claims analyses apply to this study.

CONCLUSIONS:

This real-world analysis shows significantly lower annual medical costs and HCRU with semaglutide 2.4 mg versus no semaglutide 2.4 mg treatment in patients with ov/ob and ASCVD. Improving outcomes with semaglutide 2.4 mg combined with lower costs and HCRU may help slow the growing burden of ASCVD in this population.

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes

Article

Author: Lübker, Christopher ; Lincoff, A. Michael ; Bøg, Martin ; Lingvay, Ildiko ; McEwan, Phil ; Toliver, Joshua C. ; Yeates, Florian ; Faurby, Mads ; Miller, Ryan ; Foos, Volker

AIMS:

The cardioprotective effects of semaglutide 2.4 mg reported in the SELECT cardiovascular (CV) outcomes trial (ClinicalTrials.gov NCT03574597) provide clinical benefit for subjects with overweight or obesity and established CV disease without type 2 diabetes (T2D). We assessed cost-effectiveness of semaglutide 2.4 mg in this population against the American College of Cardiology/American Heart Association value framework.

MATERIALS AND METHODS:

A cohort-level Markov-state cost-effectiveness model using trial-derived data with outcomes from a healthcare sector perspective measured over a lifetime horizon was developed. Treatment costs were based on US list prices; scenario analyses used literature-reported estimated rebates. Healthcare costs and benefits were discounted at 3.0%. A simulated cohort of 100,000 subjects was aligned to the SELECT trial population baseline characteristics and time-on-treatment. Subjects received either semaglutide 2.4 mg or placebo in addition to standard of care (SoC). Modelled outcomes included clinical events (CV events, progression to T2D, chronic kidney disease [CKD]) and health economic measures, including direct costs and quality-adjusted life years (QALYs).

RESULTS:

Mean semaglutide 2.4 mg treatment duration was 2.79 years. Per 100,000 subjects, treatment avoided 2,791 non-fatal myocardial infarctions, 3,000 coronary revascularizations, 487 non-fatal strokes, and 115 CV deaths over the modeled lifetime horizon. Average per-subject lifetime treatment costs were $47,353; savings arose from avoided T2D ($14,431), CKD ($2,074), and CV events ($1,512). Semaglutide 2.4 mg was associated with increased lifetime costs ($29,767), additional QALYs gained (0.218) and an incremental cost-effectiveness ratio of $136,271/QALY at list price; a scenario using an empirically estimated 48% rebate predicted $32,219/QALY.

LIMITATIONS:

The generalizability of observations from SELECT to a broader US population is unknown. Our model does not capture all outcomes nor costs that may be affected by weight loss. Modeling assumptions may present limitations.

CONCLUSIONS:

Semaglutide 2.4 mg use as in SELECT is cost-effective at list price, using a $150,000/QALY willingness-to-pay threshold.

01 Oct 2025·MOLECULAR AND CELLULAR ENDOCRINOLOGY

The effect of Semaglutide on mitochondrial function and insulin sensitivity in a myotube model of insulin resistance

Article

Author: Travis, Kipton B ; Zimmerman, John M ; Vaughan, Roger A ; Ragland, Kayla J ; Klein, Alexa J ; Spry, Emmalie R

AIMS:

Semaglutide (SEMA) is a glucagon-like peptide-1 receptor agonist (GLP-1RA) that has recently emerged as a popular pharmacological treatment for type 2 diabetes and insulin resistance due to its weight loss properties. Previous studies have examined the metabolic effects of SEMA using supra-pharmacokinetically (but not pharmacokinetically attainable) concentrations. The aim of the present study was to determine the metabolic effects of pharmacokinetically attainable levels of SEMA on mitochondrial function and metabolism, which are often reduced during insulin resistance.

METHODS:

C2C12 myotubes were treated for 24 h with SEMA at 10 nM which approximates pharmacokinetically attainable blood concentrations in vivo. Metabolic gene expression was measured using qRT-PCR. pAkt expression was assessed using Western blot. Seahorse metabolic assays were also used to measure mitochondrial and glycolytic metabolism. Fluorescent staining was used to assess mitochondrial and lipid content.

RESULTS:

Treatment with SEMA did not alter mitochondrial function, content, or related gene expression. Similarly, SEMA had no significant effect on glycolytic metabolism or related gene expression, nor did it alter cellular lipid content or lipogenic signaling.

CONCLUSIONS:

High concentrations of SEMA may promote mitochondrial function during in vitro experiments, however the findings from the present report suggest pharmacokinetically attainable levels of SEMA do not alter myotube metabolism or expression of related molecular targets. Disparities in the present report and past observations may be a result of the lower concentrations of SEMA used in the present experiments. Further in vivo studies will be necessary to elucidate the full metabolic effects of SEMA on skeletal muscle.

2,254

News (Medical) associated with Semaglutide (Novo Nordisk)

11 Aug 2025

·pharma.economictimes.indiatimes.com

Late to catch First wave of Semaglutide, Alembic eyes Tirzepatide opportunity, says MD

New Delhi: Amid the growing interest of Indian companies in the rapidly unfolding GLP-1 space, led by the forthcoming LOE window, under its near-focus Alembic pharmaceuticals is developing pipeline of peptides including Tirzepatide while Semaglutide is under consideration, said Pranav Amin, MD, Alembic Pharmaceuticals. In a written response to queries from ETPharma, Pranav Amin, MD, Alembic Pharmaceuticals, stated, “we are developing a differentiated pipeline of complex injectables and peptides including Tirzepatide”-- a blockbuster GIP/GLP-1 dual agonist marketed by US giant Eli Lilly under brand names Zepbound (weight-loss) and Mounjaro (type-2 diabetes). On Semaglutide which is set to lose it exclusivity by early next year, Amin said, “Semaglutide remains under consideration, but we acknowledge we were late for the initial wave of submissions in the US as well as Rest-of-world markets, and are evaluating entry in the second wave.” “While we are evaluating Semaglutide, Tirzepatide represents our near-term focus for which we are aiming to catch the first wave,” he added. Elaborating the company peptide plans—the structural foundation of GLP-1 drugs —the company MD outlined that, Alembic is expanding its strategy of backward integration (APIs) and has invested in a peptide block to manufacture peptides including GLP-1 analogs . Alembic has commissioned its sterile and onco (cancer) injectable facility in FY23, with capabilities spanning vials, lyophilized products, prefilled syringes and microsphere formulations. “Alongside our own portfolio build-out, we are also exploring select CDMO opportunities to leverage available capacity and expand customer partnerships,” Amin said. Both Semaglutide and Tirzepatide are synthetic peptides marketed by Denmark based-Novo Nordisk and US-based Eli Lilly respectively. However they represent different technological and biochemical approaches. The former is a GLP-1 agonist while Tirzepatide is a dual action therapy which targets two incretin hormone receptors, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). As per Lilly 2024 financial results the drug had reported worldwide annual sales of more than $16 billion—$11.5 billion (Mounjaro) and $4.96 billion (Zepbound). For India, a monthly sales tracker PharmaTrac , suggests, in four months since its launch the drug sales have rallied at a two-fold rate reaching ₹98 crore (gross) and ₹47 crore in July alone. Notably as several companies have already advanced their generic formulation plans to later stages like Biocon which is set to file this quarter, garnering a meaningful value traction in an increasingly crowded market remains a tough challenge. Last week, presenting the tracker July updates Sheetal Sapale, VP, Commercial Pharmarack, had noted, “once generics enter the market the game will play out on volume because extracting the same value will be difficult.” While the molecule patent expiry is still a long way off, projections of an impending obesity surge–around 500 million both men and women by Lancet—by 2030 triggered a renewed focus and a strong market potential also viewed by other leading companies such as Sun Pharma, working on their in-house innovators with plans of entering market “in five years.” By Abhijeet Singh ,

Financial StatementBiosimilar

08 Aug 2025

·firstwordpharma.com

Gilead trims assets partnered with Novo Nordisk, Arcus from pipeline

Gilead Sciences has axed half a dozen programmes from its portfolio, including candidates partnered with Novo Nordisk and Arcus Biosciences. The pipeline cull was disclosed in the company's second-quarter financial report on Thursday, when it also announced encouraging early uptake for its HIV prevention shot Yeztugo (lenacapavir) (see – Spotlight On: With Yeztugo's launch off to the races, Gilead ups HIV guidance).The pipeline prioritisation hit four cancer programmes, an experimental infectious disease asset, and Gilead's final metabolic dysfunction-associated steatohepatitis (MASH) hopeful. The drugmaker had been developing a triple-combination MASH treatment in collaboration with Novo Nordisk since at least 2020. The cocktail, comprising the Danish pharma's GLP-1 blockbuster semaglutide along with Gilead's experimental drugs cilofexor and firsocostat, was studied in the Phase II WAYFIND study.The discontinued candidates from Arcus also date back to a 2020 partnership pegged to last a decade. At the time, Gilead paid $175 million upfront and made a $200-million equity investment to co-develop and co-commercialise cancer immunotherapies from Arcus' pipeline — notably, the PD-1 inhibitor zimberelimab and several anti-TIGIT programmes, although the allure of TIGIT has since faded drastically following a number of high-profile setbacks within the class (see – Spotlight On: AstraZeneca leads TIGIT charge as another one bites the dust).In 2021, Gilead exercised options for several additional assets including etrumadenant, a dual adenosine A2a/A2b receptor antagonist, and the small-molecule CD73 inhibitor quemliclustat; both were pruned from the drugmaker's pipeline on Thursday. The partners had been studying etrumadenant in combination with zimberelimab in the Phase II ARC-9 study for metastatic colorectal cancer, while quemliclustat was being evaluated in the Phase II ARC-8 trial in patients with metastatic pancreatic ductal adenocarcinoma, with or without the PD-1 inhibitor. Separate from the Arcus partnership, Gilead also cut two Phase I oncology programmes from its portfolio: MCL1 inhibitor GS-9716 and DGKα inhibitor GS-9911.The sixth asset to get the axe was the oral antiviral obeldesivir, specifically as a treatment for respiratory syncytial virus (RSV) in both children and adults. Gilead's decision to end development in RSV doesn't come as a surprise, as two trials were terminated in June due to "lower than expected" RSV infection incident rates. At the time, Gilead told FirstWord that a 400-person Phase II study of obeldesivir in Marburg virus disease was continuing as planned. The antiviral also failed the Phase III OAKTREE trial last year after it didn't improve time to symptom alleviation versus placebo in non-hospitalised COVID-19 patients without risk factors for severe disease.

Phase 2Phase 3Clinical Trial FailureImmunotherapy

07 Aug 2025

·pharma.economictimes.indiatimes.com

Mounjaro growth in India on a 2x track, gross sales touch Rs 98 crore in July

New Delhi: Since its debut in March this year, Eli Lilly ’s blockbuster GIP/GLP-1 dual agonist, ' Tirzepatide ' is expanding footprint at a two-fold rate in India, with its brand Mounjaro racking up ₹98 crore in total sales, including ₹47 crore in July alone. According to domestic sales tracker PharmaTrac, Tirzepatide, indicated for type 2 diabetes and chronic weight management , reported net sales of ₹47 crore in July—a two-fold jump from ₹23 crore in June. Following its launch in March, Mounjaro’s monthly net sales have risen from Rs 3 crore (in its partial launch month) to Rs 8 crore, Rs 13 crore, Rs 26 crore, and most recently over ₹47 crore in July, cumulatively amounting to ₹98 crore, PharmaTrac data shows. Presenting the data during a virtual briefing, Sheetal Sapale, VP – Commercial, Pharmarack , said, “Since its launch, Mounjaro has achieved 2x growth in sales value and has established a strong prescriber base, supported by aggressive promotions.” As of July, India’s total GLP-1 market is valued at around Rs628 crore, with Semaglutide commanding the largest share, holding a moving annual turnover (MAT) of ₹421 crore, followed by Tirzepatide which has MAT of ₹98 crore. Interestingly, in July, Eli Lilly’s Mounjaro surpassed Semaglutide in monthly sales, with ₹47 crore in net sales compared to ₹38 crore for Semaglutide split as ₹7 crore from Wegovy (weekly injectable) and ₹31 crore from Rybelsus (oral tablets). In contrast, in June, Mounjaro clocked ₹23 crore while Semaglutide stood ahead at ₹31 crore, driven largely by the launch of Wegovy. Besides value, Mounjaro also outpaced Semaglutide in unit (volume) sales, with 157,000 units sold compared to 120,000 units for semaglutide—across both injectable and oral forms. “Wegovy has a strong prescriber base due to Rybelsus. However, substantial promotion may be needed to tap into the same patient base in the injectable market,” Sapale noted. “Once generics enter the market, volume will dominate, and maintaining the same value will be challenging,” she added. Notably, Novo Nordisk ’s Semaglutide, marketed under Wegovy and Rybelsus, is expected to lose patent protection in India by March 2026. Several Indian pharma majors including Cipla, Dr. Reddy’s, Lupin, Alkem, Zydus, Torrent and several others, are reportedly working on generic formulations, aiming to be among the first movers post-expiry. Responding to a query from ETPharma on the expected market outlook post-patent expiry, Sapale said, “Many pharma companies are banking on affordability. However, obesity is a condition that requires specialist intervention and proper patient segmentation.” “It’s not a molecule that should be routinely prescribed by consulting physicians. If specialists adopt generics, it could expand the patient base to some extent—but it may not be as large an opportunity as branded generics in the DPP-4i and SGLT2 categories,” she added. Meanwhile, several estimates suggest that after the entry of generics, patients could see a significant drop in treatment cost, with monthly prices potentially falling to as low as ₹4,000, down from the current range of ₹14,000 to ₹25,000, depending on the brand. By Abhijeet Singh ,

Drug ApprovalBiosimilarPatent Expiration

100 Deals associated with Semaglutide (Novo Nordisk)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10025	Semaglutide (Novo Nordisk)	A10BJ06	DB13928

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Chronic Kidney Diseases	United States	Novo Nordisk A/S	28 Jan 2025
Chronic Kidney Diseases	United States	Novo Nordisk, Inc.	28 Jan 2025
Stroke	Australia	Novo Nordisk Pharmaceuticals Pty Ltd.	16 Dec 2024
Myocardial Infarction	Canada	Novo Nordisk Canada, Inc.	27 Nov 2024
Obesity	United States	Novo Nordisk, Inc.	04 Jun 2021
Overweight	United States	Novo Nordisk, Inc.	04 Jun 2021
Diabetes Mellitus, Type 2	United States	Novo Nordisk, Inc.	05 Dec 2017

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Nonalcoholic Steatohepatitis	NDA/BLA	United States	Novo Nordisk A/S	30 Apr 2025
Albuminuria	Phase 3	Canada	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Germany	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Netherlands	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Spain	Novo Nordisk A/S	14 Mar 2022
Osteoarthritis, Knee	Phase 3	United States	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Canada	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Colombia	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Denmark	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	France	Novo Nordisk A/S	01 Oct 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03574597 (SELECT, Pubmed \| J Med Econ)	Phase 3	Cardiovascular Diseases \| Obesity	-	Semaglutide 2.4 mg	mbhboktiqf(sohjchuics) = jyqdxvhnnt kbpqjzsfqe (awqgupnkcg ) View more	Positive	31 Dec 2025
NCT05530577 (CTgov)	Phase 2	Nicotine Dependence	24	Semaglutide (Semaglutide)	zrvgyykwrt(ljjxyfxxxt) = kgaujtpkql wkgwqvdcdd (kkslrltanv, 0.63) View more	-	18 Jul 2025
				Sham/placebo (Sham/Placebo)	zrvgyykwrt(ljjxyfxxxt) = chhympixti wkgwqvdcdd (kkslrltanv, 0.69) View more
NCT04560998 (STRIDE, CTgov)	Phase 3	Diabetes Mellitus, Type 2 \| Peripheral Arterial Disease	792	Semaglutide	vhsoathovb(iywdmxkbny) = ypacpdahwh rtxtaesszc (mhewwyqwho, jwfxovwmve - spuswgkqpu) View more	-	08 Jul 2025
ACTRN12621001539820 (Pubmed) Manual	Phase 2	-	31	Semaglutide	olspamfzgz(gnzqzhglak) = rlojzqsmgh ireopghbkc (xtyxivejkx, 0.90)	Positive	01 Jul 2025
				placebo	olspamfzgz(gnzqzhglak) = rqczmexbgj ireopghbkc (xtyxivejkx, 0.93)
NCT06282458 (QUALITY, GlobeNewswire) Manual	Phase 2	Muscular Atrophy \| Obesity	148	Placebosemaglutide (after discontinuation of semaglutide; Day 112 to Day 196, ITT population)	sbwyxswrcx(ljzyavcvyd) = xiomvouada edgtlgqyrh (obcpnxtfqa, 0.40) View more	Positive	24 Jun 2025
				Enobosarm 3mgsemaglutide (after discontinuation of semaglutide; Day 112 to Day 196, ITT population)	sbwyxswrcx(ljzyavcvyd) = sggiemtqnn edgtlgqyrh (obcpnxtfqa, 0.40) View more
BELIEVE (NEWS 1 \| NEWS 2) Manual	Phase 2	Overweight \| Obesity	507	Bimagrumab	ymkabcnqkg(avzsfhlhmr) = twfcrvdqcj bbifdhphfh (yukuwfuccj ) View more	Positive	23 Jun 2025
				Semaglutide	ymkabcnqkg(avzsfhlhmr) = vghtthfdhn bbifdhphfh (yukuwfuccj ) View more
NCT05537233 (ADJUST-T1D, Pubmed \| NEJM Evid)	Phase 2	Diabetes Mellitus, Type 1 \| Obesity	72	Semaglutide up to 1 mg	ccppqlyiyh(pxmxuvpscq) = ykontgdiqm xtswzryrpe (unlxdwlcro, -10.6 to -7.0) View more	Positive	23 Jun 2025
				Placebo	-
ADA2025 Manual	Not Applicable	Obesity	23,600	Semaglutide	waslarziev(zzkuiiidqv) = Higher proportions of patients in the semaglutide group achieved weight loss thresholds of ≥10%, ≥15%, and ≥20% (p < 0.01). dwacmhgqso (efetxnevqg ) View more	Positive	20 Jun 2025
				placebo
NCT05646706 (STEP UP, ADA2025 \| NEWS) Manual	Not Applicable	Obesity	1,407	semaglutide 7.2mg	bjtmctczzh(ksisnngcqz) = rbwxqnpbxl rzdgmobqiu (bzqazxgldw ) View more	Positive	20 Jun 2025
				semaglutide 2.4mg	bjtmctczzh(ksisnngcqz) = xgjbyrfmik rzdgmobqiu (bzqazxgldw ) View more
NEWS Manual	Not Applicable	Obesity	-	Semaglutide/Tirzepatide	mtrqwiymuq(vansdektwa) = xyhepuyfhx wxxzhbzxaa (fyqfcqscxl ) View more	-	10 Jun 2025

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Semaglutide (Novo Nordisk)

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation